The invention relates to shape memory material activated devices, and more particularly, the invention relates to shape memory material activated systems, such as, temperature sensors, drug delivery systems, and the like, which employ a shape memory material activator to create a path through a shell.
Temperature warning devices are used as safety devices for products such as pharmaceuticals, foods, and beverages that are subject to loss of potency or strength, chemical alteration or degradation, spoilage, poisoning, and taste or flavor alteration if they are exposed to high temperature or thawed from a frozen condition. Typically, all products have a restricted temperature range outside of which the product begins to change. Many different types of warning devices exist which warn the consumer if the product has reached or exceed its safe temperature limits. Examples of temperature warning devices are described in U.S. Pat. Nos. 5,735,607; 5,531,180; 5,460,117; 5,335,994; and 4,664,056.
Drug delivery devices, such as transdermal patches or implantable drug delivery systems, are available for delivery of drugs to a patient. These drug delivery devices may be manually activated prior to use, such as by the removal of a peelable liner on a transdermal patch. However, it would be desirable to provide on demand activation of a drug delivery device by use of a shape memory material activator.
It would also be desirable to provide a simple and reliable shape memory activated device for use in a variety of applications.
The present invention relates to the creation of a path through a shell wall with the aid of a shape memory material. The path through the shell wall may release a substance contained in the shell or allow a substance to enter the shell. The devices according to the present invention may be used as temperature sensors or warning devices, drug delivery devices, and the like.
One aspect of the present invention relates to a temperature warning device, drug delivery device, or other device having a shell containing a first substance and an enclosure containing a second substance. Mixing of the substances is achieved by activation of a shape memory material activator. The shape memory material has been deformed in the martensitic state and its As to Af temperature range includes the predetermined temperature which is considered to be the maximum safe temperature of the product. For the temperature warning device, the enclosure is made of either a transparent or opaque material with a transparent window. Once the predetermined temperature has been reached, the shape memory material recovers its shape and in the process applies a stress (tensile, compressive, shear, torsion, or a combination) that results in the creation of a path for the two substances to come in contact. The color of the enclosure fluid changes to indicate this effect and to provide the temperature warning through the transparent window. The path creation is accomplished by the shape memory material by several means such as fracturing, exploding, imploding, puncturing, peeling, tearing, shearing, rupturing, splitting, separating, debonding etc. the shell. The method depends on the type of shell and on how the shape memory material is utilized.
In accordance with one aspect of the present invention, a temperature sensor includes a shell containing a substance capable of providing a visible indication upon release from the shell, and a shape memory material activator for creating a path through the shell to release the substance from the shell in response to exposure to a temperature which is above a maximum safe temperature.
In accordance with an additional aspect of the present invention, a shape memory material activated device for opening a shell containing a substance, the device includes a shell containing a substance, and a shape memory material activator configured to create a path through the shell in response to exposure of the shape memory material to a temperature above a predetermined temperature.
In accordance with a further aspect of the invention, a drug delivery system includes a shell containing a drug, and a shape memory material activator for creating a path to deliver the drug from the shell to a patient when a predetermined temperature of the shape memory material activator is achieved.
The invention will now be described in greater detail with reference to the preferred embodiments illustrated in the accompanying drawings, in which like elements bear like reference numerals, and wherein:
This document describes a series of inventions for devices whose principal operation is to create a path through a shell in order to release a substance. The path is created with the direct or indirect aid of a shape memory material. The shape memory material acts as a sensor to detect release temperature and activate or actuate the device to release the substance. The released substance can be utilized alone or it can be mixed with a second substance to produce a new substance with different properties for further utilization. The release rate can be instantaneous at a predetermined temperature or controlled and integrated over time and/or temperature. These systems are mechanical in nature. However, they are capable of becoming electro mechanical as will be shown later. Conversion to electro mechanical operation enhances the performance of the systems and adds further capabilities to them.
The ability to release and/or mix substances at a predetermined temperature or temperature range impart unique capabilities to these devices. Some of these capabilities are: (1) production a new color upon mixing of two substances; (2) direct or indirect absorption of a substance, externally or internally, by a mammalian body; (3) automatic initiation of a chemical reactions; (4) remote controlled mixing rate or concentration adjustment of a chemical solution. Utilization of these capabilities can result in a multitude of new or enhanced applications such as: (1) temperature warning devices and specifically, temperature indicators and time temperature integrator indicators; (2) on demand drug delivery systems; (3) color changing toys; (4) control of chemical reactions. Two of the applications, temperature indicators and on demand drug delivery systems will be used as examples during the description of the invention. However, the embodiments illustrated for one type of system are capable of use for any of the other types of systems described herein.
All inventions described herein utilize a shape memory material to act as temperature sensors and to either activate or actuate the device when the predetermined temperature has been exceeded. Alternatively, the shape memory material may also activate or actuate the device when cooled below a predetermined temperature. Most materials with reasonable shape recoveries and development of adequate stresses during the shape recovery process can be utilized for these devices. Presently Ni—Ti type and Cu based alloys adequately meet these criteria and therefore are considered good candidates for these designs. Throughout the description reference is made to a typical shape memory material Displacement vs Temperature graph shown in
Temperature warning devices are generally used as safety devices for products such as pharmaceuticals, foods, and beverages that are subject to loss of potency or strength, chemical alteration or degradation, spoilage, poisoning, and taste or flavor alteration if they are exposed to high temperature. Typically, all products have a restricted temperature range outside of which the product begins to change. The temperature warning devices described below warn the consumer if the product has reached or exceed its safe temperature limits. Although most of the description is concentrated on the high end of the temperature range, as it will be seen later, these devices can be used to provide low temperature protection or warnings. The warning provided may be by optical means, such as a color change. Besides the devices that indicate exposure to a temperature, this invention includes designs, utilizing the same principle of operation, for time and temperature integrator indicators. Temperature warning in all cases is provided by creation of a path through a shell containing a dye or other substance. The dye gets mixed with a surrounding fluid to produce a color change. The path opening is permanent for the temperature indicators while it is opened and closed, as temperature fluctuates, in a controlled manner for the time and temperature integrator indicators.
To standardize the nomenclature and avoid confusion due to multiple applications of these devices, at times the shell contents, whether they are dye, drug, solute, solvent, or anything else, will be referred to as the “source”. Also, the same contents will be referred to as the substance within the shell to distinguish them from the substance which will be the contents of the enclosure surrounding the shell.
For this to take place, a material of the shell 12 must be brittle enough not to allow itself to deform plastically without fracturing. Fracturing allows the first substance from the interior of the shell 12 to be released and, optionally, be mixed/dissolved or otherwise combined with the second substance within the reservoir 16. The color change (if there is one) is preferably visible through a window of the reservoir and becomes a warning indication that the predetermined temperature has been exceeded. Alternatively, the visible indication may indicate another event such as the release of a drug.
The term shell as used herein is intended to mean any container or enclosure which is capable of being fractured, opened, severed, stretched, or otherwise modified to allow a substance to enter or exit the shell.
A temperature at which the device 10 is activated and the mixing of the two substances begins lies between the “Austenitic start” (As) and the “Austenitic finish” (Af) temperatures of the shape memory material,
The shell in all the embodiments described herein contains the substance or drug to be released. Once the predetermined temperature is reached a path is created through the shell that allows the two substances to come into contact. The two substances can be at any state; solid, liquid, or gas. However, in this application the enclosure substance is preferably in the liquid state and the shell substance is in either the solid or liquid state. Typically, the shell substance is a dye capable of changing the enclosure's color once the two come in contact.
The path creation through the shell is achieved by activation of the shape memory material activator which creates a path by fracturing, exploding, imploding, puncturing, peeling, tearing, rupturing, splitting, or otherwise opening the shell. The shape memory material has been deformed in the martensitic state and its As to Af temperature range includes the predetermined temperature which is considered to be the maximum safe temperature of the product. The enclosure is made of either a transparent or opaque material with a transparent window. Once the predetermined temperature has been reached, the shape memory material recovers its shape and in the process applies a stress (tensile, compressive, shear, torsion, or a combination) that results in the creation of a path for the two substances to come in contact. The color of the enclosure fluid changes to indicate this effect and to provide the temperature warning through the transparent window. The path creation is accomplished by the shape memory material by several means such as fracturing, exploding, imploding, puncturing, peeling, tearing, shearing, rupturing, splitting, separating, debonding etc. the shell. The method depends on the type of shell and on how the shape memory material is utilized.
For the temperature warning device of
The actual shape of the deformed shape memory material in the martensitic state does not have to necessarily be in the form of a spring 14, as shown in
The shape memory material can be of any shape as long as during recovery it is able to (a) produce sufficient displacement to come in contact with the inside surface of the shell and, (b) produce sufficient force to create a path through the shell walls. Determining factors for the shape of the shape memory material are: the amount of displacement required, and the properties and sizes of both the shape memory material and the shell material.
If the substances contained within the shell 12, 32 and the reservoir 16, 36, prior to mixing or after mixing, react with the shape memory material to the point that either the function of the device or its effectiveness are affected, the shape memory material must be insulated from the substances. This is achieved by containing the shape memory material in a non-reactant material. Alternatively, this may be achieved by placing the shape memory material outside of the shell and/or reservoir as in the embodiments of
The shape of the shell 12, 32 depends primarily on the amount of substance it has to contain and, the shape and size of the shape memory material. The shell can consist of one or multiple parts. Also, the fabrication and assembly methods influence the shape and size of the shell. Material selection for the shell depends on both intrinsic and extrinsic factors. Intrinsic factors are material properties that must be such as to allow the shape memory material to create a path through the shell walls. Extrinsic factors are; the type of heating to be used to activate the device i.e. ambient, resistive etc. and, the time required for the device to be activated, once the surroundings have reached the predetermined temperature. Again, the material (or materials if more than one is used) must not react with the substances contained in the shell and the enclosure, prior to mixing or after mixing to the degree that the effectiveness of the device is compromised.
Instead of using a shape memory material to both activate the device and create a path through the shell walls, the shape memory material can be used for the activation process and a regular spring of non-shape memory material or a superelastic material may be used to create the path while the shape memory material is used as a release mechanism.
Materials considered useful for the non-shape memory spring element 44 include those having spring properties, such as, steel, stainless steels, Beryllium-Copper alloys, and others. The spring element 44 is restrained in a position containing stored mechanical energy by the release mechanism 48. Examples of restrained positions include compressed coil springs or bent wires (as shown in
The spring element 44 of
As illustrated in the embodiments of
In an alternative embodiment, a shape memory material tube may be flattened in the martensitic state to have an oval or other non-circular cross section. The shape memory material tube, upon transformation to the austenitic state recovers a round cross section and breaks the end seals.
A good example of this concept is the case where the contents of the shell 142 are in solid loosely packed powder form. This system offers the advantage of reduced cost by having one common enclosure 146 and shell 142 for use at all temperatures and having the shape memory material activator 144, with different As temperatures, installed at the end of the assembly process or prior to the application. Also, it avoids the storage and transportation costs associated with maintaining the devices at a temperature lower that the activation temperature prior to application.
According to one alternative embodiment of the inventions described herein, the invention may employ devices similar to the devices described herein except that the shape memory material activator activates at a minimum temperature. In this embodiment, the shape memory material activator has been trained to achieve a two way shape memory effect. The purpose of this reverse system is to detect minimum temperatures and release a substance from a shell when such a minimum temperature has been exceeded. To do so, a shape memory material is selected whose martensitic transformation range Ms to Mf includes the minimum release temperature. Initially, the shape memory material is trained to achieve a two way shape memory effect with the austenitic (recovered) shape being the installation shape and the martensitic (original) shape being the one undertaken once the material is exposed to the predetermined temperature. At this temperature the shape memory material creates a path through the shell walls and releases the substance from the shell. The shape memory material is required to exhibit the two way shape memory effect only once, when the service temperature drops below the predetermined temperature. In essence, the shape memory material in the reverse system operates in the reverse temperature cycle. Actuation takes place during cooling from austenite to martensite whereas in high temperature activation case, actuation takes place during heating, from martensite to austenite. The same features used in all of the other designs described herein can also used with the reverse system.
Time Dependent Temperature Activated Systems
In the embodiment of
According to the embodiment of
If the seal 210 is made of material that swells with exposure to fluids, the swelling (increase in volume and thereby linear dimensional increase, distance d in
If the source is in the solid state and in the form of a cone, sphere, or other shape, it must be dissolved uniformly such that it can be sealed at the end of each cycle. In the case of a time compensating drug delivery system the solid state drug source can contain a gradient of the active ingredient such that the released drug increases in potency with increased exposure time. In the case of a time integrator indicator the dye can consist of several layers of different colors (with one color being exposed at any given time) so that different colors are produced with increased exposure time. Color change will be indicative of the time exposure above or below the predetermined temperature. For better accuracy, the surface of the seal 210 in contact with the source 206 must be sealed so that any absorbed liquid will not continue to dissolve the source. Also, the shape of the drug source must be designed such that the liquid at the interface is displaced during the completion of the cycle, i.e. upon return to the martensitic state. One way this is achieved is to allow for more cushion at the first contact point, i.e. peak of cone or sphere, and decrease the amount of cushioning as the contact continues. An example of this configuration is shown in
Instead of using a shape memory material trained in two way shape memory effect, the cycling can also be accomplished with the incorporation of a bias spring 220 along with the shape memory material spring 208, as shown in the embodiment of
The time integrator indicator devices of
The same concept can be used without the swelling effect. In this case the seal must provide the cushioning and sealing, and must exhibit minimal creep in the expected operational temperature range. Again, a bias spring can be used to minimize the amnesia of the shape memory material activator and assure sufficient contact pressure to displace the fluid from the sealer/drug source interface.
In both cases, swell and no swell of the seal 210, the source 206 can be made the stationary member and the sealer 205 the moving one. In addition, as shown in
The concept used for the time dependent shell described above with respect to
The first change requires selection of the source material, membrane (if one is used) and, enclosure fluid such as to control the release or mixing rates with respect to temperature. In other words, release is both material and temperature dependent. With this system, at a constant temperature above As and with increasing time the drug release rate remains constant as time goes by. However, the release rate increases as the temperature increases. If a solid state drug source is used which is built of different strength layers, the release rate will be increasing incrementally, as each layer is dissolved, with either time itself at constant temperature or time and temperature. The strength levels and the rate of change must be calibrated for specific applications, as each application requires different temperatures and times. This concept has only a lower temperature limit. The temperature application range is bounded only at the low end which is the As temperature. Above this temperature the path through the shell wall remains open and release or dissolution of the source continuous. Upper bound is only limited by material capabilities.
The second change requires modification of the geometry of the source such that there is a progressively larger gap, tip to base, between the sealer and the source, as shown in
With this design change, the drug release rate of the time and temperature compensating drug delivery system remains constant with time at a constant temperature but it increases as the temperature increases. The increase can be designed to be either linear or non-linear. The increase in release rate translates into an increase in drug strength. In the case of time and temperature integrator indicator, the mixing rate of the dye remains constant with time at constant temperature and increases the color depth of the enclosure's fluid at a constant rate. The mixing rate of the dye increases with temperature, linearly or non-linearly, and in return it accelerates the increase in color depth accordingly. Additionally, the dye source, if used in the solid state, can be made up of several layers of different colors. Each layer as it is mixed with the enclosure's fluid will produce a new color that will reflect, in a more discerning way, the time and temperature history.
As shown in the embodiments of
As shown in
In all the embodiments discussed herein, the closing member or the shell can be made the moving part and the other part the stationary one simply by exchanging places of the shape memory material and bias springs with the compensating spring.
In all the embodiments described herein, more than one shell, containing the same or different substances, such as drugs of various degrees of potency in the case of a drug delivery system, can be used with a single enclosure. They can all be activated at the same or different temperatures. For shape memory materials to be activated at different temperatures, the chemical composition or the processing of the material must be different. Multiple shells will allow for several reactions/mixings between the two substances to take place. As an example, in a drug delivery system with multiple shells, shell #1 contains a drug that is to be released at a predetermined temperature while shell #2 contains the same drug of higher potency to be released at a higher predetermined temperature. As a second example, if each shell contains a different color dye, the fluid of the enclosure will obtain a different color at each predetermined temperature. Each color will correspond to a different temperature that will be indicative of a different level of warning.
Peelable Shell Systems
The devices illustrated in
For purposes of background, there are two types of transdermal drug delivery systems, also known as patches. One that contains the drug in a reservoir and releases it through a rate controlling membrane, and a second one which contains the drug in a polymeric matrix which is applied directly to the skin. In both cases the skin begins to absorb the drug as soon as the protective liner is removed and the patch is adhered to the skin. The device presented here takes the patch concept one step further and advances it to be qualified as an on demand transdermal drug delivery system. This is accomplished with the addition of a peelable barrier between the drug and an intermediate layer of the transdermal drug delivery system or the drug and the skin. This layer is automatically removed (peeled away) only, after the patch has been applied to the skin and only when and if there is demand for the drug.
Automatic removal of the barrier is achieved with the incorporation of a shape memory material activator in the device. Demand is determined by several ways. In the case of fever, the shape memory material can act either as both a sensor to detect the rise in temperature and as an actuator to remove the barrier layer at a predetermined temperature or simply as an actuator with the sensor being replaced with a separate temperature detection device. In the second case, activation of the shape memory material will require an external energy source to heat it and enable it to undergo the shape recovery process. In other cases such as cardiovascular and hormonal drugs, the shape memory material device is only used as an actuator with the sensing provided by added detectors. When detectors are used, microprocessors can also be incorporated to provide additional features to further enhance the self controlled characteristics of the device.
An added feature of this system is the fact that actuation can also be achieved manually. This is accomplished with the application of heat source such as a hot towel to the device. For this to work, the temperature of the applied heat source must be high enough for the shape memory material activator to undergo shape recovery. On the other hand, this temperature should not be so high as to alter the nature or potency of the drug nor should it change its ability to be absorbed by the skin.
In addition to the peelable layer, in the case of the drug reservoir type transdermal device, the shell can be placed inside the reservoir. Release of the drug into the reservoir takes place at the predetermined temperature. The reservoir may contain another drug or carrier with which it gets mixed prior to the absorption process.
In all cases, multiple shells can be used with each device to enable incremental adjustment of the drug dosage with respect to fever or other parameters.
The peelable shell drug delivery system consists of substantially the same components as the temperature warning device described above except, the substance delivered from the shell is a drug. The device incorporates a drug containing shell inside a drug reservoir. The shell encapsulates the drug to be released into the reservoir that will deliver it to the patient as a transdermal or implanted system. The reservoir can be either empty to receive the drug contained in the shell or filled with another drug to be mixed with the one released by the shell. The second option provides the advantage of extending a drug's shelf life if mixing is to take place at the time of application instead of the time of manufacturing.
Again, activation of the device 300 takes place when a shape memory material activator 312 peels the protective liner 306 which creates a path through the shell 302 for the drug to be released to the reservoir. The shape memory material can be placed either in the inside or the outside of the shell and must be compatible with the drug or be coated with a coating that is compatible with the drug. For transdermal systems verification of the release can be provided through a transparent window in the reservoir that will exhibit a color change.
As shown in the embodiments of
As shown in the embodiments of
In the embodiments of
The peelable shells can be arranged in different sizes and patterns to accommodate different requirements of temperature spans, types of sources, sequence of releases etc. In addition, the configuration of the peelable protective liners can be varied to accommodate different requirements. Some of the different patterns include shells of different widths, shells arranged in both series and parallel fashion, and shells with circular shaped or blister type drug containing cavities in series and/or parallel.
For transdermal systems the device should be designed such as to prevent any deformation of the shape memory material element during handling and application of the patch in order not to affect its performance. It is recognized that the patch is not applied to rigid flat surfaces and each application is unique in terms of geometry. In order to avoid deformation of the shape memory material during the application process, the shape memory material can be housed separately from the patch in a rigid housing and be connected to the barrier layer with a flexible conduit.
Besides the use of the coiled shape memory material spring as shown in
When the drug delivery device is a device of the type where the drug is provided in a matrix the auto-peelable barrier is placed at the bottom of the matrix. An extra liner, between the peelable barrier and the matrix would help minimize the startling effects of the sudden barrier movement during shape recovery. This layer should be transparent to the drug or contain large holes such that the most of the matrix is in contact with the skin. The matrix may be segmented and each segment having its own barrier. The barriers are removed in a “curtain” fashion with each curtain attached separately to the shape memory material activator. By varying the curtain length, each cell can be exposed to the skin at different temperature. Curtains close to the fixed end of the spring tend to produce smaller movements which necessitates smaller cells. However, by adjusting the curtain length of the individual cells, all cells can have the same size.
Another concept involves two barriers, one stationary and one mobile. Both barriers have alternating strips with cut outs of the same size. Initially, the two barriers are placed out of phase such that the drug matrix is sealed. Upon shape recovery one of the barriers begins to move exposing small areas of the matrix to the skin. At the end of the shape recovery process the strips and cutouts of the two barriers are in phase and maximum exposure is achieved.
Release Mechanisms
The following description relates to shape memory material activated release mechanisms, such as described above with respect to
Mechanism can also be used in the impact shell devices shown in
As shown in
As shown in
Several type of release mechanisms can be employed with this concept. The type depends on temperature-release precision required, space availability, design flexibility, compatibility, ease of path creation etc. Different types of release mechanisms are discussed with respect to
A series of concepts for release mechanisms to be used in conjunction with any of the embodiments described herein are described with reference to
To allow for the case where the temperature rises above As and drops to below As before it reaches Af and release is not achieved, a bias spring 520 attached to posts 522 is incorporated in the embodiment of
When mechanisms as the ones described above that release stored mechanical energy to activate the device are used to release a drug an auditory signal is emitted the strength of which depends on factors such as material of construction and medium the signal has to travel. This property becomes significant for implants where a manual adjustment of a drug dosage can be detected with device such as a stethoscope. This provides assurance of the drug release and eliminates the uncertainty or the requirement for radiography.
Drug Delivery
The following is an explanation of some of the applications of the embodiments described herein for use in drug delivery systems. On demand drug delivery system applications are subdivided into four general categories as follows:
(1) A first application is a transdermal system that is activated by rising body temperature. In this application the patch is applied when fever is anticipated due to upcoming flu symptoms, a disease or a drug side effect etc. However, there is no need for the drug until the fever rises to a critical temperature. With this device, although the patch may be worn, the drug is not released until the critical temperature is reached. The advantage of this application is the elimination of orally administered drugs, elimination of temperature measurement, and the fact that the drug is used only if and when it is needed. More, background, information on transdermal systems is presented below.
(2) A second application involves transdermal systems used to deliver drugs but not activated by rising body temperature. In this case, the device must be activated with an external energy source when the need for the drug arises. For automatic activation the energy source has to be stored electrical energy (batteries) while for manual activation heat applied directly to the device, such as by a hot compress, will suffice. One example of this case is insulin delivered drugs.
(3) A third application involves implantable drug delivery systems. Again, for an automatic operation, a self-contained energy source is required. For manual operation an external heat source is required. In this case heat is conducted through the body to raise the temperature of the shape memory material and activate the device.
(4) A fourth application involves mixing of predetermined quantities of two or more drugs. This is a useful application when there is a need to mix two or more drugs without having to measure them. This need may arise from field work where it is not convenient to measure or when the shelf life of a drug is extended when mixing takes place at the time of application.
Electric Activation
For greater flexibility, a more accurate temperature activation system, and better time response, the shape memory material, coupled with a separate temperature sensor and the appropriate controls to activate the device, can be used as the means to generate the force to fracture the shell. Types of temperature sensors that can be used are: thermocouples, resistive temperature devices (RTDs and thermistors), IC temperature sensors etc. Irrespective of the sensor type, an energy source such as a battery will be required to provide heat to the shape memory material in order to undergo the phase transformation and create a path through the shell. With this system, means must be provided to connect the Shape memory material to the power source and electrically insulate it to avoid short circuits and energy leaks. One advantage of this system is the ability to have the temperature sensor and the enclosure placed in to two different locations, as long as they are connected together. The controls (microprocessor, solenoid, switch etc.) can be placed either inside the enclosure or outside. Because, in this case, the shape memory material is no longer the temperature sensor its As temperature has to be higher than the activation temperature of the system in order to avoid premature activation. With an electrically activated system, activation does not have to be due to temperature. Different parameters can be used for activation. This enhances the system considerably when it is used as a drug delivery system.
Insulation
To add a time delay at temperature the shape memory material and/or the enclosure can be insulated. The level of insulation will depend on the time delay desired. This feature will delay the triggering of the device until thermal equilibrium between the shape memory material and ambient is reached. The delayed trigger will be more representative of the product temperature in the case where the device is used for temperature warning. Insulation can be in the form of a jacket similar to the insulation used for electrical wires. Space can be left between the jacket and the shape memory material to be filled with thermally insulating material to further delay the shape recovery process. In no case should the insulation impede the performance of the device.
While the invention has been described in detail with reference to the preferred embodiments thereof, it will be apparent to one skilled in the art that various changes and modifications can be made and equivalents employed, without departing from the present invention.
This application is a continuation of application Ser. No. 11/436,612, filed May 19, 2006, now U.S. Pat. No. 7,287,485, which in turn is a continuation of application Ser. No. 10/744,768, filed Dec. 22, 2003, now U.S. Pat. No. 7,048,730, which in turn is a continuation of application Ser. No. 09/815,643, filed Mar. 23, 2001, now U.S. Pat. No. 6,682,521, which claims the benefit of U.S. Provisional Patent Application No. 60/191,703, filed Mar. 23, 2000, entitled Temperature Activated Systems.
Number | Name | Date | Kind |
---|---|---|---|
1622545 | Schellenberger | Mar 1927 | A |
1625014 | Amodio | Apr 1927 | A |
2125419 | Birk | Aug 1938 | A |
2460215 | Chase | Jan 1949 | A |
2580414 | Duffey | Jan 1952 | A |
2601440 | Kerrigan | Jun 1952 | A |
2866338 | Mucheryan | Dec 1958 | A |
2953921 | Mucheryan | Sep 1960 | A |
2966261 | Bradbury | Dec 1960 | A |
3214278 | Mylo | Oct 1965 | A |
3291617 | Barker et al. | Dec 1966 | A |
3440997 | Rogen et al. | Apr 1969 | A |
3483752 | Rogen et al. | Dec 1969 | A |
3516082 | Cooper | Jun 1970 | A |
3559839 | Seethaler | Feb 1971 | A |
3659600 | Merill | May 1972 | A |
3734348 | White et al. | May 1973 | A |
4114559 | Rogen | Sep 1978 | A |
4148748 | Hanion et al. | Apr 1979 | A |
4165359 | Thomas et al. | Aug 1979 | A |
4239040 | Hosoya et al. | Dec 1980 | A |
4280361 | Sala | Jul 1981 | A |
4425117 | Hugemann et al. | Jan 1984 | A |
4439197 | Honda et al. | Mar 1984 | A |
4481952 | Pawelec | Nov 1984 | A |
4507115 | Kambara et al. | Mar 1985 | A |
4522147 | Kroll et al. | Jun 1985 | A |
4539929 | Sestak et al. | Sep 1985 | A |
4564363 | Bagnall et al. | Jan 1986 | A |
4627850 | Deters et al. | Dec 1986 | A |
4664056 | Jehanno | May 1987 | A |
4872584 | Sakai | Oct 1989 | A |
4896728 | Wolff et al. | Jan 1990 | A |
4950258 | Kawai et al. | Aug 1990 | A |
5018874 | Weynant nee Girones | May 1991 | A |
5045064 | Idriss | Sep 1991 | A |
5076197 | Darringer et al. | Dec 1991 | A |
5119555 | Johnson | Jun 1992 | A |
5143453 | Weynant nee Girones | Sep 1992 | A |
5147351 | Wagner | Sep 1992 | A |
5167626 | Casper et al. | Dec 1992 | A |
5170801 | Casper et al. | Dec 1992 | A |
5176275 | Bowie | Jan 1993 | A |
5196002 | Hanover et al. | Mar 1993 | A |
5207666 | Idriss et al. | May 1993 | A |
5217449 | Yuda et al. | Jun 1993 | A |
5245738 | Johnson | Sep 1993 | A |
5279607 | Schentag et al. | Jan 1994 | A |
5335994 | Weynant nee Girones | Aug 1994 | A |
5405614 | D'Angelo et al. | Apr 1995 | A |
5443851 | Christie et al. | Aug 1995 | A |
5460117 | Loustaunau | Oct 1995 | A |
5487484 | Bonniau et al. | Jan 1996 | A |
5531180 | Bianchini | Jul 1996 | A |
5618269 | Jacobsen et al. | Apr 1997 | A |
5626581 | Staehlin et al. | May 1997 | A |
5662587 | Grundfest et al. | Sep 1997 | A |
5735607 | Shahinpoor et al. | Apr 1998 | A |
5771742 | Bokaie et al. | Jun 1998 | A |
5821664 | Shahinpoor | Oct 1998 | A |
5831417 | Chu | Nov 1998 | A |
5843700 | Kerrod et al. | Dec 1998 | A |
6048337 | Svedman | Apr 2000 | A |
6082153 | Schoell et al. | Jul 2000 | A |
6200317 | Aalsma et al. | Mar 2001 | B1 |
6237590 | Leedom et al. | May 2001 | B1 |
6375638 | Nason et al. | Apr 2002 | B2 |
6425343 | Akers et al. | Jul 2002 | B1 |
6454759 | Krulevitch et al. | Sep 2002 | B2 |
6612739 | Shahinpoor | Sep 2003 | B2 |
6648814 | Kim et al. | Nov 2003 | B2 |
6656158 | Mahoney et al. | Dec 2003 | B2 |
6656159 | Flaherty | Dec 2003 | B2 |
6688828 | Post | Feb 2004 | B1 |
6702734 | Kim et al. | Mar 2004 | B2 |
6723072 | Flaherty et al. | Apr 2004 | B2 |
6802811 | Slepian | Oct 2004 | B1 |
6837620 | Shahinpoor | Jan 2005 | B2 |
6911004 | Kim et al. | Jun 2005 | B2 |
6928812 | Donakowski et al. | Aug 2005 | B2 |
6953455 | Cho et al. | Oct 2005 | B2 |
6960192 | Flaherty et al. | Nov 2005 | B1 |
7018360 | Flaherty et al. | Mar 2006 | B2 |
7048730 | Petrakis | May 2006 | B2 |
20010016710 | Nason et al. | Aug 2001 | A1 |
20020055717 | Ponet | May 2002 | A1 |
20020161328 | Rogers | Oct 2002 | A1 |
20030065250 | Chiel et al. | Apr 2003 | A1 |
20030128491 | Ruiz et al. | Jul 2003 | A1 |
20030216622 | Meron et al. | Nov 2003 | A1 |
20040024382 | Cho et al. | Feb 2004 | A1 |
20040115067 | Rush et al. | Jun 2004 | A1 |
20050055014 | Coppeta et al. | Mar 2005 | A1 |
20050105587 | Shahinpoor | May 2005 | A1 |
20050160858 | Mernoe | Jul 2005 | A1 |
20050186273 | Yum et al. | Aug 2005 | A1 |
20050192561 | Mernoe | Sep 2005 | A1 |
20050235732 | Rush | Oct 2005 | A1 |
20070248661 | Andra et al. | Oct 2007 | A1 |
20080051635 | Tanaka et al. | Feb 2008 | A1 |
20080063703 | Gross et al. | Mar 2008 | A1 |
Number | Date | Country |
---|---|---|
2619731 | Sep 1987 | FR |
2290467 | Jan 1996 | GB |
58135808 | Aug 1983 | JP |
58194809 | Nov 1983 | JP |
60-209-673 | Oct 1985 | JP |
62-121-877 | Jun 1987 | JP |
1080775 | Mar 1989 | JP |
1188799 | Jul 1989 | JP |
02161326 | Jun 1990 | JP |
3100376 | Apr 1991 | JP |
5221468 | Aug 1993 | JP |
5221469 | Aug 1993 | JP |
08007116 | Jan 1996 | JP |
08310562 | Nov 1996 | JP |
09313520 | Dec 1997 | JP |
2004257274 | Sep 2004 | JP |
2004278495 | Oct 2004 | JP |
WO 9417379 | Aug 1994 | WO |
Number | Date | Country | |
---|---|---|---|
20080066675 A1 | Mar 2008 | US |
Number | Date | Country | |
---|---|---|---|
60191703 | Mar 2000 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 11436612 | May 2006 | US |
Child | 11979066 | US | |
Parent | 10744768 | Dec 2003 | US |
Child | 11436612 | US | |
Parent | 09815643 | Mar 2001 | US |
Child | 10744768 | US |